Stockholm · Seed–Growth · 34 people tracked
Also known as HEALTHCAP ADVISOR AB · HEALTHCAP IX ADVISOR AB · HEALTHCAP VII ADVISOR AB · HEALTHCAP VIII ADVISOR AB
Find your way into HealthCap
170 people in our graph share verified history with the HealthCap team — schools, employers, funds. One of them is your warm intro.
Investment thesis
HealthCap invests in and helps build life science companies developing breakthrough therapies with a high unmet medical need. It focuses on emerging therapeutics, particularly targeted treatments for rare diseases, cancers, and genetic diseases. The firm emphasizes deep medical expertise across medicine, finance, and biochemistry, and aims to challenge existing medical paradigms to find new ways to treat or cure diseases and improve quality of life. HealthCap stresses a responsible and sustainable approach to investing and ownership, collaborating with investors, academia, portfolio companies, patients, and other societal stakeholders to create long-term value and positive impact.
Source: firm website, verified Sep 15, 2026.
Team · 34 people
from the firm's website & curated & public directories
What they invest in
from 33 of 40 portfolio companiesBiotech ×28Healthtech ×25Medical Devices ×20Digital Health ×8Deep Tech ×4Hardware ×2AgTech ×1AI & Machine Learning ×1
HQs:United States×11Sweden×9Switzerland×1Finland×1France×1United Kingdom×1
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×62 founders×53 founders×14+ founders×2
What their founders studiedfrom 14 founders with field-of-study data
Life Sciences ×8Medicine ×3
Where their founders worked beforefrom 13 founders with career history
Göteborgs universitet ×2
Investments · 40 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22023 · 12022 · 22021 · 12020 · 32017 · 12015 · 22005 · 12004 · 115 dated
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.
BiotechHealthtechMedical DevicesSan Jose, US
LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)inGlendon E. French(Chief Executive Officer and Director)Derrick Sung(Chief Operating Officer and Chief Financial Officer)inGeoffrey Beran Rose(Chief Commercial Officer)
Board seatStaffan Lindstrand· per SEC Form D
Co-investorsBand of AngelsKaiser Permanente VenturesLatterell Venture PartnersAlly Bridge GroupMontreux Equity Partners
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)inSamir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg, M.D., M.P.H.(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)in
Board seatJonas Hansson· per SEC Form D
Co-investorsAisling CapitalRiverVest Venture PartnersAbingworthNorwest Venture PartnersNovo HoldingsOmega Funds+1 more
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyAvoro Capital AdvisorsNovo HoldingsSofinnova PartnersAvoro VenturesRA Capital
Doctrin provides a digital communication platform for healthcare providers to manage patient interactions and case management, including medical history taking, triage, collaboration tools, and chat/video capabilities.
Digital HealthEnterprise SoftwareHealthtechSaaSStockholm, GB
Gesynta Pharma is a pharmaceutical company developing non-hormonal, anti-inflammatory drug candidates that inhibit the mPGES-1 enzyme, with a lead program in endometriosis.
BiotechDigital HealthFemTechMedical DevicesStockholm, SE
Patric Stenberg(Founder)Gunilla Ekström(Founder)in
Co-investorsAmboy Street VenturesForeground CapitalHadean VenturesIndustrifondenXGEN VentureCatalyze Capital
Oncorena is a Swedish pharmaceutical company developing a breakthrough treatment for metastatic renal cancer based on the drug candidate ONC175 (orellanine).
BiotechHealthtechMedical DevicesStockholm, SE
Börje Haraldsson(Research lead)inJenny NyströminUlf NilssonLisa BuvallinPål FalckinSusanna Dahlgren(Chief Operating Officer)in
Co-investorsFSG
Priothera is a clinical-stage biotech developing mocravimod (an S1P receptor modulator) for hematologic malignancies such as acute myeloid leukemia.
BiotechHealthtech
Florent Gros(Chief Executive Officer and Founder)Stephan Oehen(Chief Operating Officer and Founder)inBrice Suire(Chief Financial Officer and Founder)Nigel Clark(Chief Business Officer)Jens Hasskarl(Chief Medical Officer)
Co-investorsFountain Healthcare Partners4see Ventures
SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.
BiotechHealthtechMedical Devices
Ray Barlow(Chief Executive Officer)in
Co-investorsBioqube VenturesForbionGimvMedicxi
Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.
BiotechHealthtech
Ole Kaasbøll(Co-founder)
Co-investorsIndustrifondenInnovestor VenturesLifeArc VenturesInvestinorNovo Holdings
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.
BiotechHealthtechParis, FR
Co-investorsKurma PartnersNovartis Venture FundRoche Venture FundYsios CapitalColumbus Venture PartnersEurazeo+1 more
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.
BiotechDigital HealthMedical DevicesBrisbane, US
Carlos A. Schuler(Executive Officer, Director)inJohn S. Patton(Executive Officer, Director)inRangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)inMiller Samantha(Executive Officer)
BoardMcCarthy Reenie(Director)
Board seatJohan Christenson· per SEC Form D
Co-investorsAsset Management CompanySofinnova VenturesDeerfield Management Company
BiotechRaleigh, US
Jaikrishna Patel(Executive Officer)Pierre Legault(Executive Officer, Director)inJames Mitchum(Director)John Hamill(Executive Officer)in
BoardRobert Seltzer(Director)
Board seatEugen Steiner· per SEC Form D · $28.5M raise · filed Nov 2015
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesJeito CapitalNovo HoldingsOrbiMedPontifax Venture CapitalRA Capital+2 more
AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLinköping, SE
Magnus Borga(Co-Founder)inOlof Dahlqvist Leinhard(Chief Executive Officer, Co-Founder)in
Co-investorsPfizer Venture Investments
RxList is an online medical resource providing detailed pharmaceutical information on brand and generic drugs, written and reviewed by pharmacists and physicians.
Digital HealthHealthtechMedia & EntertainmentSan Clemente, US
Co-investorsAlleyCorpAnzu PartnersIn-Q-TelMaverick SiliconSamsung VenturesSIP Global Partners+2 more
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.
BiotechDigital HealthMedical DevicesDoylestown, US
John P. Hamill(Executive Officer)inOren Gilad(Chief Executive Officer, President)in
BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)
Co-investors5AM VenturesVersant Ventures
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)Bruce Peacock(Director)
Co-investorsAvego BioScience CapitalAgent CapitalBiotechnology Value FundCowen Healthcare InvestmentsJohnson & Johnson Innovation – JJDCNorthpond Ventures
BiotechSan Leandro, US
Steve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)inStephen W. Lau(President, Chief Executive Officer, and Treasurer)inKenneth Schwartz(Executive Officer)inEric Yuen(Executive Officer)inMarten Steen(Director)in
Co-investorsInkefSectoral Asset ManagementSofinnova VenturesYsios Capital
BoneSupport develops synthetic bone graft substitutes that remodel to match patient bone and elute antibiotics to prevent infection during healing.
BiotechHealthtechMedical Devices
Co-investorsIndustrifonden
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB Invesment CorporationAnzu PartnersGrazia Equity GmbHMRL Ventures FundSolasta Ventures+3 more
CurifyLabs develops an automated compounding system for pharmacies that uses robotics, GMP-manufactured excipient bases, and integrated quality control software to enable faster, safer preparation of customized medications.
Digital HealthHealthtechMedical DevicesHelsinki, FI
Charlotta Topelius(CEO & Founder)inNiklas Sandler TopeliusNiklas Sandler(CTO & Founder)in
Co-investorsLifeline VenturesSandwater
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
Co-investorsFACIT (Fight Against Cancer Innovation Trust)Lumira VenturesSeroba Life SciencesVenture OntarioYsios CapitalAdams Street Partners+2 more
Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
BiotechDeep TechHealthtechMedical Devices
Mohit Trikha(CEO)inSophia Randolph(Chief Medical Officer)in
Co-investorsBOMM VenturesRed Tree VentureBioGeneration VenturesNovo Holdings
Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.
BiotechHealthtechSouth San Francisco, US
Yael Weiss(Executive Officer, Director)in
BoardCamille Samuels(Director)inMarten Steen(Director)inShalini Sharp(Director)inStephen Farr(Director)
Co-investorsDroia VenturesMitsui Global InvestmentVenrockVenrock Associates
Neobiomics develops multi-strain food supplements rooted in academic research, with collaborations across Europe.
BiotechFoodTechHealthtechMedical DevicesWellness & FitnessStockholm, SE
Philipp Novak(Co-founder)inStefan Johansson(MD PhD, CMO)in
Oncopeptides develops therapeutics for cancer treatment.
BiotechHealthtechMedical Devices
Co-investorsIndustrifonden
OxThera develops a live biotherapeutic product based on oxalate-degrading bacteria to treat primary hyperoxaluria and other rare kidney diseases.
BiotechHealthtechMedical DevicesStockholm, SE
Elisabeth Lindner(Chief Operating Officer)Mats-Olof Wallin(Chief Financial Officer)Milt Allison
Co-investorsSunstone CapitalYsios Capital
Positrigo develops functional imaging technology to make diagnostic and clinical imaging scalable and accessible globally.
Deep TechHardwareHealthtechMedical Devices
Jannis Fischer(Founder)in
Co-investorskineo finance
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)inGabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)
Co-investorsARCH Venture PartnersCambridge Innovation CapitalEIR VenturesAngelini VenturesGV (Google Ventures)
Vicore Pharma is a clinical-stage biopharmaceutical company developing disease-modifying treatments for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis.
BiotechHealthtechMedical Devices
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AriceumAriceum TherapeuticsCortendoElsa Science ABHellobetterHowtogetridofwartshomeNucleonicsPRECIRIX NV
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
3 IPOsPulmonx Corp.NASDAQ: LUNGSpruce BiosciencesNASDAQ: SPRBHemab TherapeuticsNASDAQ: COAG
Portfolio news
latest coverage across their companies
Spruce Biosciences · stocktitan.net · Aug 14, 2026
Aprea · tradingview.com · Aug 12, 2026
Pulmonx Corp. · defenseworld.net · Jul 19, 2026
CurifyLabs · arctictoday.com · Jul 15, 2026
Adcendo ApS · geekwire.com · Jul 13, 2026
Mahzi Therapeutics · forbes.com · Jul 13, 2026
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Hemab Therapeutics | 4.3% | $18.00 | May 2026 | $34.1M |
| Spruce Biosciences | 8.0% | $15.00 | Oct 2020 | $26.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has HealthCap made?
- HealthCap has 40 tracked investments, 3 of which have exited, including 3 dated in the last 24 months.
- What stage does HealthCap invest at?
- HealthCap invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does HealthCap focus on?
- HealthCap focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is HealthCap located?
- HealthCap is headquartered in Stockholm, SE.
- Who does HealthCap co-invest with?
- HealthCap most often shares deals with Industrifonden, Novo Holdings, Pfizer Venture Investments, among 61 tracked co-investors.
Media · Podcasts & interviews
featuring the teamHealthcare Direkt v.49: Varför är styrelsen viktig? Gäst: Staffan Lindstrand, Partner Healthcap
Direkt Studios · Staffan Lindstrand
Images
Co-investors · 11
Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Cambridge Innovation Capital (CIC) is a UK-based venture capital firm backing entrepreneurs in life sciences and deep tech, leveraging its position in the Cambridge science and technology ecosystem.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Pureos Bioventures is a venture capital firm that invests in private, innovative drug development companies, with a focus on next-generation biological drugs and drug formats to treat severe diseases.
Earlybird Venture Capital is a European venture capital investor that backs early-stage technology founders with capital, strategic support, and access to an international network.
Firms observed investing alongside HealthCap, from public investor directories. Shared companies are the overlap with HealthCap's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Averin Capital is an investment firm focused on the intersection of technology and health, backing teams building companies in areas such as early disease detection, treatment delivery, personalized care, and medical breakthroughs.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Gore Range Capital is a specialized healthcare investment firm building science-led platforms across precision health, regenerative medicine, personalized therapeutics, and longevity. It provides strategic, financial, and clinical guidance to portfolio companies developing next-generation healthcare solutions.